Optimum Hole-Opening Condition for Cisplatin Incorporation in Single-Wall Carbon Nanohorns and Its Release

Ajima, Kumiko; Maigné, Alan; Yudasaka, Masako; Iijima, Sumio

doi:10.1021/jp064915x

Cited by 58 publications

(33 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The exterior and interior pores inherent to SWNHs can be tailored for loading specific drugs by controlling their synthesis process. SWNHs can release controlled amounts of chemotheraputic drugs into tumors to effectively treat cancer [26,27]. The controllable release, ability to store chemotheraputic drugs, and absorption characteristics make SWNHs a strong candidate for both drug delivery and photothermal treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Intratracheal instillation tests found some incidences of foamy macrophages and anthracosis, but neither resulted in increased mortality rates [21,25]. Furthermore, the extensive surface area, multitude of interstices inherent to SWNHs, and accessible internal volume permit the addition of guest molecules [26]. This makes them an exceptional nanoplatform for drug delivery [18,19].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Single walled carbon nanohorns as photothermal cancer agents

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Single walled carbon nanohorns as photothermal cancer agents

et al. 2011

View full text Add to dashboard Cite

show abstract

“…6A). If carbon nanohorns are used (carbon nanotubes with rounded ends that cap the particles), then holes can be created in the tubes by heating them up to 500 8C before the drug is loaded (Ajima et al 2006). Release of platins from the nanotubes is controlled either through diffusion or through the use of iron nanoparticle caps A schematic diagram showing a unique method of attaching a platin drug to the surface of gold nanoparticles.…”

Section: Carbon Nanotubesmentioning

confidence: 99%

The state-of-play and future of platinum drugs

Apps

Choi

Wheate

2015

Endocrine-Related Cancer

230

142

View full text Add to dashboard Cite

The year 2015 marks the 50th anniversary since the discovery of the anticancer potential of cisplatin and it remains just as useful now as it did back then, especially for the treatment of some endocrine-related cancers like ovarian and testicular carcinomas. Since its discovery, five other platin drugs have received approval in various countries. While several new platin drugs are in preclinical development, in the last decade only two new platin drugs have entered clinical trials, LA-12 and dicycloplatin, reflecting a shift in research focus from new drug design to improved formulations of already approved platin drugs. These formulations include their encapsulation with macrocycles to slow and prevent their degradation by proteins and peptides; their attachment to nanoparticles to passively target solid tumours through the enhanced permeability and retention effect and their coordination to important nutrients, proteins, antibodies and aptamers for active tumour targeting. These formulation methods have all shown potential but none have yet yielded a new marketable medicine containing a platin drug. The reasons for this are problems of consistent drug loading, controlling the location and timing of drug release and the inherent toxicity of some of the drug delivery vehicles. In addition to drug delivery, functional genomics is now playing an increasing role in predicting patients' responses to platin chemotherapy and their likelihood of experiencing severe side effects.

show abstract

“…Here, Cisplatin (Cis-Diamminedichloroplatinum (CDDP)) has been used. The inclusion of Cisplatin has already involved a new variety of SWCNTs: the single-wall carbon nanohorns (SWCNHs), graphitic tubes with cone shaped tips and the characteristic feature to assemble in spherical aggregates [5][6][7].…”

mentioning

confidence: 99%

Cisplatin functionalized single‐walled carbon nanotubes

Tripisciano

Borowiak‐Palen

2008

Physica Status Solidi (b)

View full text Add to dashboard Cite

The use of chemotherapeutic agents is nowadays limited by the damage they inflict to healthy tissues. Due to the fact that Carbon nanotubes (CNTs) possess the characteristic feature of being not degraded in the human body, they can be used to deliver small organic drug molecules into the diseased cells thus preventing normal tissue damages. Here, the functionalization of acid treated Single‐Walled CNTs with Cisplatin (Cis‐Diamminedichloroplatinum (CDDP)), a potent anticancer agent which suffers of toxic side‐effects and lack of selectivity, is presented. Raman Spectroscopy was exploited to estimate the purity of SWNTs sample and via Infrared (IR) analysis the characterization of the functional groups formed upon the acid treatment was performed. The morphology characterization was carried out with high resolution transmission electron microscopy (HR‐TEM), and Raman spectroscopy. Additionally, the CDDP release from the samples in physiological solution was studied using UV‐VIS Spectroscopy and Inductively coupled plasma (ICP) analysis. (© 2008 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim)

show abstract

Optimum Hole-Opening Condition for Cisplatin Incorporation in Single-Wall Carbon Nanohorns and Its Release

Cited by 58 publications

References 12 publications

Single walled carbon nanohorns as photothermal cancer agents

Single walled carbon nanohorns as photothermal cancer agents

The state-of-play and future of platinum drugs

Cisplatin functionalized single‐walled carbon nanotubes

Contact Info

Product

Resources

About